Skip to main content
KalVista Pharmaceuticals, Inc logo
Menu toggle

Main navigation

  • About KalVista
    • Senior Management
    • Board of Directors
    • Contact Us
    • Careers
  • Products & Pipeline
    • Pipeline
    • KalVista for HAE
    • Sebetralstat
    • KVD824
    • Factor XIIa
    • KalVista for DME
    • Publications
  • For Patients
    • Clinical Studies
    • HAE Resources
    • Sebetralstat
    • KVD824
    • Factor XIIa
    • DME Resources
  • For Healthcare Providers
    • HAE Resources
    • Sebetralstat
    • KVD824
    • Factor XIIa
    • DME Resources
    • Publications
    • Expanded Access
  • For Investors
    • Stock Information
    • News Releases
    • Events Calendar
    • Presentations
    • SEC Filings
    • Analyst Coverage
    • Corporate Governance

Creating a new generation of small molecule protease inhibitors for HAE and DME

Hereditary Angioedema (HAE)

Diabetic Macular Edema (DME)

Positive Phase 2 Data for Oral KVD900 in Hereditary Angioedema (HAE)

For more information, click here

Reduced use of rescue treatment for HAE attack

graph 1

Mild to moderate HAE attacks treated with Sebetralstat significantly reduced use of rescue (p=0.001), with 15% of Sebetralstat treated attacks rescued compared to 30% on placebo at 12 hours.

Reduced time to symptom relief on PGI-C scale

graph 2

Sebetralstat significantly reduced time to onset of symptom relief after HAE attacks on a Patient Global Impression of Change scale (PGI-C), with median time of 1.6 hours with Sebetralstat vs. 9 hours for with placebo (p=<0.0001).

Sustained cumulative symptom relief as assessed by VAS

clock

Cumulative symptom relief (defined as 50% reduction in composite VAS score for three consecutive time points) was maintained at 24 hours (p=0.0005) vs. placebo.

Sebetralstat is an investigational product candidate currently in clinical development as an oral on-demand therapy for HAE attacks.

News

Kalvista Pharmaceuticals

KalVista Pharmaceuticals Announces Non-Proprietary Name Selection for KVD900

May 17, 2022
Kalvista Pharmaceuticals

KalVista Pharmaceuticals to Present at 21st Annual Needham Virtual Healthcare Conference

Apr 11, 2022
Kalvista Pharmaceuticals

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 4, 2022
All News

Footer

  • About KalVista
  • Products & Pipeline
  • For Patients
  • For Healthcare Providers
  • For Investors
  • Contact Us
+1 (857) 999 0075 info@kalvista.com medinfo@kalvista.com

Social Menu

  • Linked In
  • Twitter
Copyright © 2022 | All rights reserved.

Footer Bottom

  • KalVista Terms
  • Privacy